. 2015 Mar; 15(4):201-15.
doi: 10.1038/nrc3907.

Haematological malignancies: at the forefront of immunotherapeutic innovation

Pavan Bachireddy 1 Ute E Burkhardt 2 Mohini Rajasagi 3 Catherine J Wu 1 
  • PMID: 25786696
  •     203 References
  •     33 citations


The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
Vincent T Ho, Matthew Vanneman, +14 authors, Robert Soiffer.
Proc Natl Acad Sci U S A, 2009 Sep 01; 106(37). PMID: 19717467    Free PMC article.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.
Robert R Jenq, Marcel R M van den Brink.
Nat Rev Cancer, 2010 Feb 20; 10(3). PMID: 20168320
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.
Megan E Murray, Catherine M Gavile, +8 authors, Kelvin P Lee.
Blood, 2014 May 02; 123(24). PMID: 24782505    Free PMC article.
Multiple myeloma.
Antonio Palumbo, Kenneth Anderson.
N Engl J Med, 2011 Mar 18; 364(11). PMID: 21410373
Highly Cited. Review.
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Yoshihiro Oka, Akihiro Tsuboi, +15 authors, Haruo Sugiyama.
Int J Hematol, 2003 Aug 05; 78(1). PMID: 12894852
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.
Jochen Greiner, Michael Schmitt, +8 authors, Lars Bullinger.
Blood, 2006 Aug 26; 108(13). PMID: 16931630
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, +9 authors, Margaret A Shipp.
Blood, 2010 Jul 16; 116(17). PMID: 20628145    Free PMC article.
Highly Cited.
Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Jochen Greiner, Mark Ringhoffer, +8 authors, Michael Schmitt.
Exp Hematol, 2002 Sep 13; 30(9). PMID: 12225794
Posttransplantation vaccination: concepts today and on the horizon.
Katayoun Rezvani.
Hematology Am Soc Hematol Educ Program, 2011 Dec 14; 2011. PMID: 22160049
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Jeffrey J Molldrem, Peter P Lee, +5 authors, Mark M Davis.
J Clin Invest, 2003 Mar 06; 111(5). PMID: 12618518    Free PMC article.
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
E M Sotomayor, I Borrello, +6 authors, H I Levitsky.
Nat Med, 1999 Jul 08; 5(7). PMID: 10395323
Highly Cited.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Yu-Tzu Tai, Myles Dillon, +19 authors, Kenneth C Anderson.
Blood, 2007 Oct 02; 112(4). PMID: 17906076    Free PMC article.
Highly Cited.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Michael L Wang, Simon Rule, +28 authors, Kristie A Blum.
N Engl J Med, 2013 Jun 21; 369(6). PMID: 23782157    Free PMC article.
Highly Cited.
Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells.
Daniel T Patton, Oliver A Garden, +8 authors, Klaus Okkenhaug.
J Immunol, 2006 Nov 04; 177(10). PMID: 17082571
Highly Cited.
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Arnold Freedman, Sattva S Neelapu, +9 authors, Paul Hamlin.
J Clin Oncol, 2009 May 06; 27(18). PMID: 19414675    Free PMC article.
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Kathleen Cathcart, Javier Pinilla-Ibarz, +4 authors, David A Scheinberg.
Blood, 2003 Sep 25; 103(3). PMID: 14504104
Expression of the Wilms' tumor gene (WT1) in human leukemias.
H Miwa, M Beran, G F Saunders.
Leukemia, 1992 May 01; 6(5). PMID: 1317488
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications.
Lindsey M Hoffman, Lia Gore.
Front Oncol, 2014 Apr 20; 4. PMID: 24744989    Free PMC article.
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Benjamin Uttenthal, Irma Martinez-Davila, +8 authors, Emma C Morris.
Br J Haematol, 2014 Jan 16; 164(3). PMID: 24422723    Free PMC article.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, +16 authors, Stephan A Grupp.
N Engl J Med, 2014 Oct 16; 371(16). PMID: 25317870    Free PMC article.
Highly Cited.
Vaccine adjuvants: putting innate immunity to work.
Robert L Coffman, Alan Sher, Robert A Seder.
Immunity, 2010 Oct 30; 33(4). PMID: 21029960    Free PMC article.
Highly Cited. Review.
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
Joshua Richter, Natalia Neparidze, +6 authors, Madhav V Dhodapkar.
Blood, 2012 Oct 27; 121(3). PMID: 23100308    Free PMC article.
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
R R French, H T Chan, A L Tutt, M J Glennie.
Nat Med, 1999 May 06; 5(5). PMID: 10229232
Highly Cited.
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
Jacalyn Rosenblatt, Baldev Vasir, +16 authors, David Avigan.
Blood, 2010 Oct 30; 117(2). PMID: 21030562    Free PMC article.
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh, François Ghiringhelli, +25 authors, Laurence Zitvogel.
Nat Med, 2007 Aug 21; 13(9). PMID: 17704786
Highly Cited.
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
Jürgen Kuball, Karin de Boer, +11 authors, Matthias Theobald.
Cancer Immunol Immunother, 2010 Oct 22; 60(2). PMID: 20963411    Free PMC article.
Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.
Elena Muraro, Debora Martorelli, Riccardo Dolcetti.
Hum Vaccin Immunother, 2013 Feb 15; 9(5). PMID: 23406835    Free PMC article.
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
SaeGwang Park, Zhujun Jiang, +11 authors, Yang-Xin Fu.
Cancer Cell, 2010 Aug 17; 18(2). PMID: 20708157    Free PMC article.
Highly Cited.
Dendritic cell immunotherapy: mapping the way.
Carl G Figdor, I Jolanda M de Vries, W Joost Lesterhuis, Cornelis J M Melief.
Nat Med, 2004 May 04; 10(5). PMID: 15122249
Highly Cited. Review.
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.
Paul Greaves, Andrew Clear, +6 authors, John G Gribben.
Blood, 2013 Sep 06; 122(16). PMID: 24004665    Free PMC article.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A Akbay, Shohei Koyama, +24 authors, Kwok-Kin Wong.
Cancer Discov, 2013 Oct 01; 3(12). PMID: 24078774    Free PMC article.
Highly Cited.
A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Sophie Dessureault, David Noyes, +6 authors, Scott J Antonia.
Ann Surg Oncol, 2006 Nov 15; 14(2). PMID: 17103257
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Jeffrey M Venstrom, Gianfranco Pittari, +8 authors, Katharine C Hsu.
N Engl J Med, 2012 Aug 31; 367(9). PMID: 22931314    Free PMC article.
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
Andreas S Baur, Manfred B Lutz, +17 authors, Gerold Schuler.
Blood, 2013 Aug 21; 122(13). PMID: 23958949
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, +29 authors, Renier Brentjens.
Sci Transl Med, 2014 Feb 21; 6(224). PMID: 24553386    Free PMC article.
Highly Cited.
Effect of alemtuzumab on neoplastic B cells.
Josée Golay, Massimiliano Manganini, Alessandro Rambaldi, Martino Introna.
Haematologica, 2004 Dec 14; 89(12). PMID: 15590398
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Ganesh Suntharalingam, Meghan R Perry, +4 authors, Nicki Panoskaltsis.
N Engl J Med, 2006 Aug 16; 355(10). PMID: 16908486
Highly Cited.
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Laurence Zitvogel, Lorenzo Galluzzi, Mark J Smyth, Guido Kroemer.
Immunity, 2013 Jul 31; 39(1). PMID: 23890065
Highly Cited. Review.
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
Ute E Burkhardt, Ursula Hainz, +28 authors, Catherine J Wu.
J Clin Invest, 2013 Aug 06; 123(9). PMID: 23912587    Free PMC article.
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
Pavan Bachireddy, Ursula Hainz, +15 authors, Catherine J Wu.
Blood, 2013 Dec 21; 123(9). PMID: 24357730    Free PMC article.
Advances in targeting cell surface signalling molecules for immune modulation.
Sheng Yao, Yuwen Zhu, Lieping Chen.
Nat Rev Drug Discov, 2013 Feb 02; 12(2). PMID: 23370250    Free PMC article.
Highly Cited. Review.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li Li, Krzysztof Giannopoulos, +8 authors, Michael Schmitt.
Int J Oncol, 2006 Mar 10; 28(4). PMID: 16525634
Cancer immunotherapy comes of age.
Suzanne L Topalian, George J Weiner, Drew M Pardoll.
J Clin Oncol, 2011 Nov 02; 29(36). PMID: 22042955    Free PMC article.
Highly Cited. Review.
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.
Li Jia, Andrew Clear, +7 authors, John G Gribben.
Blood, 2014 Jan 28; 123(11). PMID: 24464016    Free PMC article.
BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.
José M Rojas, Katy Knight, +4 authors, Richard E Clark.
Leuk Res, 2010 Jun 25; 35(3). PMID: 20573399
Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy.
R E Brouwer, K H Zwinderman, +3 authors, J H Falkenburg.
Exp Hematol, 2000 Mar 08; 28(2). PMID: 10706072
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Veronika Bachanova, Sarah Cooley, +11 authors, Jeffrey S Miller.
Blood, 2014 Apr 11; 123(25). PMID: 24719405    Free PMC article.
Highly Cited.
CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
W G Wierda, M J Cantwell, +3 authors, T J Kipps.
Blood, 2000 Oct 26; 96(9). PMID: 11049967
T cell exhaustion.
E John Wherry.
Nat Immunol, 2011 Jul 09; 12(6). PMID: 21739672
Highly Cited. Review.
A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.
Toshio Kitawaki, Norimitsu Kadowaki, +10 authors, Takashi Uchiyama.
Br J Haematol, 2011 Apr 12; 153(6). PMID: 21477159
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
John C Byrd, Richard R Furman, +18 authors, Susan O'Brien.
N Engl J Med, 2013 Jun 21; 369(1). PMID: 23782158    Free PMC article.
Highly Cited.
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Alan G Ramsay, Amy J Johnson, +5 authors, John G Gribben.
J Clin Invest, 2008 Jun 14; 118(7). PMID: 18551193    Free PMC article.
Highly Cited.
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
William G Wierda, Thomas J Kipps, +18 authors, Hx-CD20-406 Study Investigators.
J Clin Oncol, 2010 Mar 03; 28(10). PMID: 20194866    Free PMC article.
Highly Cited.
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Joao T Barata, Ana Silva, +3 authors, Vassiliki A Boussiotis.
J Exp Med, 2004 Sep 09; 200(5). PMID: 15353558    Free PMC article.
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
J M Rojas, K Knight, L Wang, R E Clark.
Leukemia, 2007 Jul 20; 21(11). PMID: 17637811
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Stephen M Ansell, Sara A Hurvitz, +10 authors, John M Timmerman.
Clin Cancer Res, 2009 Oct 08; 15(20). PMID: 19808874    Free PMC article.
Highly Cited.
Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
J Molldrem, S Dermime, +5 authors, A J Barrett.
Blood, 1996 Oct 01; 88(7). PMID: 8839835
Antibody therapeutics in cancer.
Mark X Sliwkowski, Ira Mellman.
Science, 2013 Sep 14; 341(6151). PMID: 24031011
Highly Cited. Review.
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
Don M Benson, Craig C Hofmeister, +9 authors, Sherif S Farag.
Blood, 2012 Oct 04; 120(22). PMID: 23033266    Free PMC article.
Highly Cited.
The tumour microenvironment in B cell lymphomas.
David W Scott, Randy D Gascoyne.
Nat Rev Cancer, 2014 Jul 11; 14(8). PMID: 25008267
Highly Cited. Review.
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
Jacalyn Rosenblatt, Irit Avivi, +22 authors, David Avigan.
Clin Cancer Res, 2013 May 21; 19(13). PMID: 23685836    Free PMC article.
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Ranjana Advani, Andres Forero-Torres, +6 authors, Jonathan G Drachman.
J Clin Oncol, 2009 Jul 29; 27(26). PMID: 19636010
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
Philippe Armand, Arnon Nagler, +21 authors, Leo I Gordon.
J Clin Oncol, 2013 Oct 16; 31(33). PMID: 24127452    Free PMC article.
Highly Cited.
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
Jaehyup Kim, Ryan A Denu, +5 authors, Peiman Hematti.
Br J Haematol, 2012 May 16; 158(3). PMID: 22583117    Free PMC article.
Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention.
Wieger J Norde, Willemijn Hobo, Robbert van der Voort, Harry Dolstra.
Blood, 2012 May 09; 120(4). PMID: 22563087
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
Thomas E Witzig, Gregory A Wiseman, +17 authors, George J Weiner.
Am J Hematol, 2013 Apr 27; 88(7). PMID: 23619698    Free PMC article.
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
J A Burger, N Tsukada, +3 authors, T J Kipps.
Blood, 2000 Oct 07; 96(8). PMID: 11023495
Highly Cited.
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.
Shahryar Kiaii, Andrew J Clear, +6 authors, John G Gribben.
J Clin Oncol, 2013 Jun 19; 31(21). PMID: 23775959    Free PMC article.
CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.
A Cignetti, E Bryant, +3 authors, M A Cheever.
Blood, 1999 Sep 09; 94(6). PMID: 10477734
Replacing the complementarity-determining regions in a human antibody with those from a mouse.
P T Jones, P H Dear, +2 authors, G Winter.
Nature, 1986 May 04; 321(6069). PMID: 3713831
Highly Cited.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Anas Younes, Ajay K Gopal, +15 authors, Robert Chen.
J Clin Oncol, 2012 Mar 29; 30(18). PMID: 22454421    Free PMC article.
Highly Cited.
CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies.
Todd W Kelley, Charles J Parker.
Front Biosci (Schol Ed), 2010 Jun 03; 2(3). PMID: 20515837
B regulatory cells in cancer.
Frances Balkwill, Anne Montfort, Melania Capasso.
Trends Immunol, 2012 Dec 05; 34(4). PMID: 23206438
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Tait D Shanafelt, Alan G Ramsay, +9 authors, Neil E Kay.
Blood, 2013 Mar 16; 121(20). PMID: 23493782
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.
Abigail M Lee, Andrew J Clear, +8 authors, Lindsey K Goff.
J Clin Oncol, 2006 Oct 13; 24(31). PMID: 17033038
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.
Giovanni F Torelli, Nadia Peragine, +11 authors, Robin Foà.
Haematologica, 2014 Mar 25; 99(7). PMID: 24658822    Free PMC article.
IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway.
Louise Swainson, Sandrina Kinet, +3 authors, Naomi Taylor.
Blood, 2006 Oct 07; 109(3). PMID: 17023582
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.
Weiyun Z Ai, Robert Tibshirani, +2 authors, Ronald Levy.
Blood, 2009 Apr 07; 113(23). PMID: 19346494    Free PMC article.
A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.
W G Wierda, J E Castro, +6 authors, T J Kipps.
Leukemia, 2010 Oct 01; 24(11). PMID: 20882050    Free PMC article.
Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones.
D T Umetsu, L Esserman, +2 authors, R Levy.
J Immunol, 1990 Apr 01; 144(7). PMID: 1969451
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Michael Schmitt, Anita Schmitt, +17 authors, Jochen Greiner.
Blood, 2007 Nov 06; 111(3). PMID: 17978170
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, +16 authors, Philippe Armand.
N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239    Free PMC article.
Highly Cited.
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Neha Korde, Mattias Carlsten, +20 authors, Ola Landgren.
Haematologica, 2014 Mar 25; 99(6). PMID: 24658821    Free PMC article.
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Stephen J Schuster, Sattva S Neelapu, +16 authors, Larry W Kwak.
J Clin Oncol, 2011 Jun 03; 29(20). PMID: 21632504    Free PMC article.
Highly Cited.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
Massimo Di Nicola, Roberta Zappasodi, +10 authors, Alessandro M Gianni.
Blood, 2008 Sep 24; 113(1). PMID: 18809757
Bone marrow as a priming site for T-cell responses to blood-borne antigen.
Markus Feuerer, Philipp Beckhove, +8 authors, Volker Schirrmacher.
Nat Med, 2003 Aug 12; 9(9). PMID: 12910264
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Daniel Ribeiro, Alice Melão, João T Barata.
Adv Biol Regul, 2012 Dec 14; 53(2). PMID: 23234870
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Joshua D Brody, Weiyun Z Ai, +10 authors, Ronald Levy.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697067    Free PMC article.
Highly Cited.
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
B Douglas Smith, Yvette L Kasamon, +13 authors, Hyam I Levitsky.
Clin Cancer Res, 2010 Jan 06; 16(1). PMID: 20048335    Free PMC article.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
David L Porter, Bruce L Levine, +2 authors, Carl H June.
N Engl J Med, 2011 Aug 13; 365(8). PMID: 21830940    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
Danelle F James, Lillian Werner, +9 authors, Thomas J Kipps.
J Clin Oncol, 2014 May 29; 32(19). PMID: 24868031    Free PMC article.
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.
Mariela Sivina, Elena Hartmann, +14 authors, Jan A Burger.
Blood, 2010 Dec 01; 117(5). PMID: 21115978    Free PMC article.
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
R A Clynes, T L Towers, L G Presta, J V Ravetch.
Nat Med, 2000 Mar 31; 6(4). PMID: 10742152
Highly Cited.
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.
S A Riemersma, E S Jordanova, +4 authors, P M Kluin.
Blood, 2000 Nov 09; 96(10). PMID: 11071656
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.
Zhi-Zhang Yang, Deanna M Grote, +5 authors, Stephen M Ansell.
J Clin Invest, 2012 Mar 20; 122(4). PMID: 22426209    Free PMC article.
Highly Cited.
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Katayoun Rezvani, Agnes S M Yong, +6 authors, A John Barrett.
Blood, 2007 Sep 19; 111(1). PMID: 17875804    Free PMC article.
Highly Cited.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Asad Bashey, Bridget Medina, +11 authors, Edward D Ball.
Blood, 2008 Nov 01; 113(7). PMID: 18974373    Free PMC article.
Highly Cited.
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Jeffrey S Miller, Yvette Soignier, +14 authors, Philip B McGlave.
Blood, 2005 Jan 06; 105(8). PMID: 15632206
Highly Cited.
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
Rao H Prabhala, Dheeraj Pelluru, +13 authors, Nikhil C Munshi.
Blood, 2010 Apr 17; 115(26). PMID: 20395418    Free PMC article.
Highly Cited.
Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.
F T Hakim, R Cepeda, +5 authors, R E Gress.
Blood, 1997 Nov 14; 90(9). PMID: 9345067
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, +10 authors, Robert H Vonderheide.
Science, 2011 Mar 26; 331(6024). PMID: 21436454    Free PMC article.
Highly Cited.
Innate or adaptive immunity? The example of natural killer cells.
Eric Vivier, David H Raulet, +5 authors, Sophie Ugolini.
Science, 2011 Jan 08; 331(6013). PMID: 21212348    Free PMC article.
Highly Cited. Review.
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
Raphaël F Rousseau, Ettore Biagi, +13 authors, Malcolm K Brenner.
Blood, 2005 Oct 27; 107(4). PMID: 16249392    Free PMC article.
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
Mohini Rajasagi, Sachet A Shukla, +16 authors, Catherine J Wu.
Blood, 2014 Jun 04; 124(3). PMID: 24891321    Free PMC article.
Highly Cited.
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.
John C Riches, Jeffrey K Davies, +5 authors, John G Gribben.
Blood, 2012 Dec 19; 121(9). PMID: 23247726    Free PMC article.
Highly Cited.
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Jan Krönke, Namrata D Udeshi, +14 authors, Benjamin L Ebert.
Science, 2013 Dec 03; 343(6168). PMID: 24292625    Free PMC article.
Highly Cited.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
R Eric Davis, Vu N Ngo, +34 authors, Louis M Staudt.
Nature, 2010 Jan 08; 463(7277). PMID: 20054396    Free PMC article.
Highly Cited.
Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes.
Fabien Guilloton, Gersende Caron, +10 authors, Karin Tarte.
Blood, 2012 Feb 01; 119(11). PMID: 22289889
Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
K Giannopoulos, A Dmoszynska, +8 authors, M Schmitt.
Leukemia, 2010 Mar 12; 24(4). PMID: 20220777
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Catherine M Bollard, Stephen Gottschalk, +17 authors, Cliona M Rooney.
J Clin Oncol, 2013 Dec 18; 32(8). PMID: 24344220    Free PMC article.
Highly Cited.
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.
Sarah Cooley, Daniel J Weisdorf, +11 authors, Jeffrey S Miller.
Blood, 2010 Jun 29; 116(14). PMID: 20581313    Free PMC article.
Highly Cited.
Regulation of mature T cell homeostasis.
Charles D Surh, Jonathan Sprent.
Semin Immunol, 2005 Apr 14; 17(3). PMID: 15826823
Spontaneous regression in non-Hodgkin's lymphoma.
H H Gattiker, E Wiltshaw, D A Galton.
Cancer, 1980 May 15; 45(10). PMID: 7378996
Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases.
Ilaria Del Giudice, Sabina Chiaretti, +9 authors, Robin Foà.
Blood, 2009 Apr 24; 114(3). PMID: 19387007
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Sagar Lonial, Ravi Vij, +9 authors, Sundar Jagannath.
J Clin Oncol, 2012 May 02; 30(16). PMID: 22547589
Highly Cited.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Valentin Goede, Kirsten Fischer, +20 authors, Michael Hallek.
N Engl J Med, 2014 Jan 10; 370(12). PMID: 24401022
Highly Cited.
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.
Kimberly Noonan, Luigi Marchionni, +3 authors, Ivan Borrello.
Blood, 2010 Jul 29; 116(18). PMID: 20664052    Free PMC article.
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.
J J Molldrem, P P Lee, +4 authors, M M Davis.
Nat Med, 2000 Sep 06; 6(9). PMID: 10973322
Highly Cited.
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Susana Inogès, Mercedes Rodrìguez-Calvillo, +15 authors, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
J Natl Cancer Inst, 2006 Sep 21; 98(18). PMID: 16985248
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Clinical targeting of the TNF and TNFR superfamilies.
Michael Croft, Chris A Benedict, Carl F Ware.
Nat Rev Drug Discov, 2013 Jan 22; 12(2). PMID: 23334208    Free PMC article.
Highly Cited. Review.
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.
R A Miller, D G Maloney, R Warnke, R Levy.
N Engl J Med, 1982 Mar 04; 306(9). PMID: 6173751
Highly Cited.
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Loredana Ruggeri, Marusca Capanni, +9 authors, Andrea Velardi.
Science, 2002 Mar 16; 295(5562). PMID: 11896281
Highly Cited.
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
M Bocchia, S Gentili, +9 authors, F Lauria.
Lancet, 2005 Feb 22; 365(9460). PMID: 15721470
A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
I Borrello, E M Sotomayor, S Cooke, H I Levitsky.
Hum Gene Ther, 1999 Aug 31; 10(12). PMID: 10466632
Combining immunotherapy and targeted therapies in cancer treatment.
Matthew Vanneman, Glenn Dranoff.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437869    Free PMC article.
Highly Cited. Review.
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
Holbrook E Kohrt, Roch Houot, +11 authors, Ronald Levy.
Blood, 2011 Jan 05; 117(8). PMID: 21193697    Free PMC article.
Highly Cited.
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
Marcela V Maus, Stephan A Grupp, David L Porter, Carl H June.
Blood, 2014 Mar 01; 123(17). PMID: 24578504    Free PMC article.
Highly Cited. Review.
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Ulrich Keilholz, Anne Letsch, +7 authors, Carmen Scheibenbogen.
Blood, 2009 Apr 25; 113(26). PMID: 19389880
Highly Cited.
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
Joaquim Carreras, Armando Lopez-Guillermo, +6 authors, Alison H Banham.
Blood, 2006 Jul 11; 108(9). PMID: 16825494
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
Paul Greaves, Andrew Clear, +7 authors, John G Gribben.
J Clin Oncol, 2012 Oct 10; 31(2). PMID: 23045593    Free PMC article.
Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.
B A Choudhury, J C Liang, +7 authors, D F Claxton.
Blood, 1999 Jan 28; 93(3). PMID: 9920826
KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.
Lena Oevermann, Sebastian U Michaelis, +7 authors, Rupert Handgretinger.
Blood, 2014 Aug 15; 124(17). PMID: 25115891    Free PMC article.
Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells.
G J Ossenkoppele, A G M Stam, +4 authors, R J Scheper.
Leukemia, 2003 Jul 02; 17(7). PMID: 12835739
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
Jason R Westin, Fuliang Chu, +19 authors, Sattva S Neelapu.
Lancet Oncol, 2013 Dec 18; 15(1). PMID: 24332512    Free PMC article.
Highly Cited.
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Katayoun Rezvani, Agnes S M Yong, +8 authors, A John Barrett.
Haematologica, 2010 Dec 08; 96(3). PMID: 21134985    Free PMC article.
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
George S Laszlo, Chelsea J Gudgeon, +7 authors, Roland B Walter.
Blood, 2013 Dec 07; 123(4). PMID: 24311721    Free PMC article.
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.
Marcus Dühren-von Minden, Rudolf Übelhart, +11 authors, Hassan Jumaa.
Nature, 2012 Aug 14; 489(7415). PMID: 22885698
Highly Cited.
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.
Davide Bagnara, Matthew S Kaufman, +15 authors, Nicholas Chiorazzi.
Blood, 2011 Mar 10; 117(20). PMID: 21385850    Free PMC article.
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
Charles H Redfern, Troy H Guthrie, +14 authors, John F Bender.
J Clin Oncol, 2006 Jun 07; 24(19). PMID: 16754937
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Christian Steidl, Sohrab P Shah, +24 authors, Randy D Gascoyne.
Nature, 2011 Mar 04; 471(7338). PMID: 21368758    Free PMC article.
Highly Cited.
Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
Katayoun Rezvani, Agnes S M Yong, +6 authors, A John Barrett.
Blood, 2007 May 17; 110(6). PMID: 17505014    Free PMC article.
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
Radek Spisek, Anjli Kukreja, +14 authors, Madhav V Dhodapkar.
J Exp Med, 2007 Mar 29; 204(4). PMID: 17389240    Free PMC article.
The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori.
T Hussell, P G Isaacson, J E Crabtree, J Spencer.
Lancet, 1993 Sep 04; 342(8871). PMID: 8102718
Highly Cited.
CD20 as a target for therapeutic type I and II monoclonal antibodies.
Stephen A Beers, Claude H T Chan, +2 authors, Martin J Glennie.
Semin Hematol, 2010 Mar 31; 47(2). PMID: 20350657
Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
I Hus, M Schmitt, +7 authors, J Roliński.
Leukemia, 2008 Mar 08; 22(5). PMID: 18323802
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Christine Galustian, Brendan Meyer, +10 authors, Angus G Dalgleish.
Cancer Immunol Immunother, 2008 Nov 15; 58(7). PMID: 19009291
Highly Cited.
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Jeffrey A Zonder, Ann F Mohrbacher, +6 authors, Anil K Singhal.
Blood, 2011 Dec 21; 120(3). PMID: 22184404    Free PMC article.
Highly Cited.
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Max S Topp, Nicola Gökbuget, +22 authors, Ralf C Bargou.
Blood, 2012 Oct 02; 120(26). PMID: 23024237
Highly Cited.
Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
K Giannopoulos, L Li, +7 authors, M Schmitt.
Int J Oncol, 2006 Jun 15; 29(1). PMID: 16773189
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Katharine C Hsu, Carolyn A Keever-Taylor, +6 authors, Bo Dupont.
Blood, 2005 Feb 26; 105(12). PMID: 15731175    Free PMC article.
Highly Cited.
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
Maurizio Bendandi.
Nat Rev Cancer, 2009 Aug 25; 9(9). PMID: 19701243
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Jeffrey E Rubnitz, Hiroto Inaba, +5 authors, Wing Leung.
J Clin Oncol, 2010 Jan 21; 28(6). PMID: 20085940    Free PMC article.
Highly Cited.
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Norbert Vey, Jean-Henri Bourhis, +9 authors, Daniel Olive.
Blood, 2012 Sep 25; 120(22). PMID: 23002117
Highly Cited.
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
B N Savani, A Montero, +3 authors, A J Barrett.
Bone Marrow Transplant, 2005 Oct 06; 36(11). PMID: 16205732
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.
L Gao, I Bellantuono, +4 authors, H J Stauss.
Blood, 2000 Mar 25; 95(7). PMID: 10733485
CD28-mediated regulation of multiple myeloma cell proliferation and survival.
Nizar J Bahlis, Anne M King, +8 authors, Kelvin P Lee.
Blood, 2007 Feb 22; 109(11). PMID: 17311991    Free PMC article.
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Priscila P Zenatti, Daniel Ribeiro, +19 authors, João T Barata.
Nat Genet, 2011 Sep 06; 43(10). PMID: 21892159    Free PMC article.
Highly Cited.
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
Jan A Burger, Maite P Quiroga, +4 authors, Andreas Rosenwald.
Blood, 2008 Dec 17; 113(13). PMID: 19074730    Free PMC article.
Highly Cited.
The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon.
Nat Rev Cancer, 2012 Mar 16; 12(4). PMID: 22419253
Highly Cited. Review.
Induction of tumor immunity following allogeneic stem cell transplantation.
Catherine J Wu, Jerome Ritz.
Adv Immunol, 2006 May 30; 90. PMID: 16730263
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
Gaynor J Bates, Stephen B Fox, +4 authors, Alison H Banham.
J Clin Oncol, 2006 Dec 01; 24(34). PMID: 17135638
Highly Cited.
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
John L Reagan, Jorge J Castillo.
Expert Rev Anticancer Ther, 2011 Feb 24; 11(2). PMID: 21342032
Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.
A A Cardoso, J L Schultze, +7 authors, L M Nadler.
Blood, 1996 Jul 01; 88(1). PMID: 8704200
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
H Miles Prince, Madeleine Duvic, +6 authors, Andres Negro-Vilar.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212249
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Viggo F Van Tendeloo, Ann Van de Velde, +20 authors, Zwi N Berneman.
Proc Natl Acad Sci U S A, 2010 Jul 16; 107(31). PMID: 20631300    Free PMC article.
Highly Cited.
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.
M Kawano, T Hirano, +7 authors, H Tanaka.
Nature, 1988 Mar 03; 332(6159). PMID: 3258060
Highly Cited.
High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
Joaquim Carreras, Armando Lopez-Guillermo, +7 authors, Elias Campo.
J Clin Oncol, 2009 Feb 20; 27(9). PMID: 19224853
HLA-binding properties of tumor neoepitopes in humans.
Edward F Fritsch, Mohini Rajasagi, +3 authors, Catherine J Wu.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894089    Free PMC article.
Highly Cited. Review.
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.
Tanja Maier, Adrian Tun-Kyi, +4 authors, Frank O Nestle.
Blood, 2003 Apr 26; 102(7). PMID: 12714511
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.
Kavya Rakhra, Pavan Bachireddy, +9 authors, Dean W Felsher.
Cancer Cell, 2010 Nov 03; 18(5). PMID: 21035406    Free PMC article.
Highly Cited.
Medicine. How thalidomide works against cancer.
A Keith Stewart.
Science, 2014 Jan 18; 343(6168). PMID: 24436409    Free PMC article.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Yoshihiro Oka, Akihiro Tsuboi, +23 authors, Haruo Sugiyama.
Proc Natl Acad Sci U S A, 2004 Sep 15; 101(38). PMID: 15365188    Free PMC article.
Highly Cited.
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, +10 authors, Christian Gisselbrecht.
N Engl J Med, 2002 Jan 25; 346(4). PMID: 11807147
Highly Cited.
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Barbara Pro, Ranjana Advani, +11 authors, Andrei Shustov.
J Clin Oncol, 2012 May 23; 30(18). PMID: 22614995
Highly Cited.
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
Bruce D Cheson, John P Leonard.
N Engl J Med, 2008 Aug 09; 359(6). PMID: 18687642
Highly Cited. Review.
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Ronald Levy, Kristen N Ganjoo, +23 authors, Dan W Denney.
J Clin Oncol, 2014 May 07; 32(17). PMID: 24799467    Free PMC article.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Deborah A Knight, Shin Foong Ngiow, +11 authors, Mark J Smyth.
J Clin Invest, 2013 Mar 05; 123(3). PMID: 23454771    Free PMC article.
Highly Cited.
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Michael Kalos, Bruce L Levine, +4 authors, Carl H June.
Sci Transl Med, 2011 Aug 13; 3(95). PMID: 21832238    Free PMC article.
Highly Cited.
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Nitin Jain, James M Reuben, +7 authors, Jorge Cortes.
Cancer, 2009 Jun 19; 115(17). PMID: 19536894    Free PMC article.
Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias.
W Digel, M Schmid, +3 authors, F Porzsolt.
Blood, 1991 Aug 01; 78(3). PMID: 1859888
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
T A Davis, A J Grillo-López, +7 authors, R Levy.
J Clin Oncol, 2000 Aug 30; 18(17). PMID: 10963642
Highly Cited.
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
M Bendandi, C D Gocke, +11 authors, L W Kwak.
Nat Med, 1999 Sep 30; 5(10). PMID: 10502821
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).
E M Ocio, P G Richardson, +31 authors, J F S Miguel.
Leukemia, 2013 Nov 21; 28(3). PMID: 24253022    Free PMC article.
Highly Cited. Review.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Jason A Dubovsky, Kyle A Beckwith, +26 authors, John C Byrd.
Blood, 2013 Jul 28; 122(15). PMID: 23886836    Free PMC article.
Highly Cited.
Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.
K Inoue, H Ogawa, +11 authors, H Sugiyama.
Blood, 1997 Feb 15; 89(4). PMID: 9028964
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Claude Preudhomme, Joëlle Guilhot, +22 authors, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).
N Engl J Med, 2010 Dec 24; 363(26). PMID: 21175313
Highly Cited.
T cell immune reconstitution following lymphodepletion.
Kirsten M Williams, Frances T Hakim, Ronald E Gress.
Semin Immunol, 2007 Nov 21; 19(5). PMID: 18023361    Free PMC article.
Highly Cited. Review.
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Franco Locatelli, Pietro Merli, Sergio Rutella.
J Leukoc Biol, 2013 Oct 08; 94(6). PMID: 24096380
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Peter G Maslak, Tao Dao, +12 authors, David A Scheinberg.
Blood, 2010 Apr 20; 116(2). PMID: 20400682    Free PMC article.
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
Helen E Heslop, Karen S Slobod, +11 authors, Cliona M Rooney.
Blood, 2009 Nov 03; 115(5). PMID: 19880495    Free PMC article.
Highly Cited.
The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours.
Francisco Vega, L Jeffrey Medeiros, +3 authors, Dan Jones.
Br J Haematol, 2002 May 25; 117(3). PMID: 12028024
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Reshaping human antibodies for therapy.
L Riechmann, M Clark, H Waldmann, G Winter.
Nature, 1988 Mar 24; 332(6162). PMID: 3127726
Highly Cited.
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Wen-Kai Weng, Ronald Levy.
J Clin Oncol, 2003 Sep 17; 21(21). PMID: 12975461
Highly Cited.
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
L M Nadler, J Ritz, +3 authors, P Stashenko.
J Clin Invest, 1981 Jan 01; 67(1). PMID: 6969730    Free PMC article.
Highly Cited.
The role of B7 family molecules in hematologic malignancy.
Paul Greaves, John G Gribben.
Blood, 2012 Dec 12; 121(5). PMID: 23223433    Free PMC article.
Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
R T Costello, F Mallet, +3 authors, D Olive.
Eur J Immunol, 1998 Mar 04; 28(1). PMID: 9485189
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.
Romain Guièze, Catherine J Wu.
Blood, 2015 Jun 13; 126(4). PMID: 26065654    Free PMC article.
Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Tiansuo Zhao, He Ren, +8 authors, Jihui Hao.
Oncotarget, 2015 Sep 01; 6(29). PMID: 26315113    Free PMC article.
Myeloid-derived suppressor cells in B cell malignancies.
Yaghoub Yazdani, Mousa Mohammadnia-Afrouzi, +5 authors, Farhad Jadidi-Niaragh.
Tumour Biol, 2015 Sep 04; 36(10). PMID: 26330296
Cellular immunotherapy as a beacon of hope for hematological malignancies.
Hyun-Ju Lee, Sang-Ki Kim, Duck Cho, Je-Jung Lee.
Blood Res, 2015 Oct 13; 50(3). PMID: 26457276    Free PMC article.
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Ciara L Freeman, John G Gribben.
Curr Hematol Malig Rep, 2016 Feb 10; 11(1). PMID: 26857283    Free PMC article.
Leukaemia 'firsts' in cancer research and treatment.
Mel Greaves.
Nat Rev Cancer, 2016 Feb 26; 16(3). PMID: 26911190
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.
Andrew L Sochacki, Melissa A Fischer, Michael R Savona.
Onco Targets Ther, 2016 May 05; 9. PMID: 27143923    Free PMC article.
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
Samantha M Gromek, James A deMayo, +7 authors, Marcy J Balunas.
Bioorg Med Chem, 2016 Sep 12; 24(21). PMID: 27614919    Free PMC article.
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seyoung Seo, Jung Yong Hong, +12 authors, Cheolwon Suh.
Oncotarget, 2016 Oct 21; 7(47). PMID: 27764777    Free PMC article.
Recent advances in T-cell immunotherapy for haematological malignancies.
Rayne H Rouce, Sandhya Sharma, Mai Huynh, Helen E Heslop.
Br J Haematol, 2016 Nov 30; 176(5). PMID: 27897332    Free PMC article.
'Trained immunity': consequences for lymphoid malignancies.
Wendy B C Stevens, Mihai G Netea, Arnon P Kater, Walter J F M van der Velden.
Haematologica, 2016 Dec 03; 101(12). PMID: 27903713    Free PMC article.
Antigen Loss Variants: Catching Hold of Escaping Foes.
Maulik Vyas, Rolf Müller, Elke Pogge von Strandmann.
Front Immunol, 2017 Mar 14; 8. PMID: 28286501    Free PMC article.
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.
David A Braun, Catherine J Wu.
Cancer J, 2017 Apr 15; 23(2). PMID: 28410299    Free PMC article.
Immunotherapy in hematologic malignancies: past, present, and future.
Annie Im, Steven Z Pavletic.
J Hematol Oncol, 2017 Apr 25; 10(1). PMID: 28434396    Free PMC article.
Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.
Abdulraouf Ramadan, Brad Griesenauer, +5 authors, Sophie Paczesny.
J Exp Med, 2017 Oct 19; 214(12). PMID: 29038366    Free PMC article.
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, +67 authors, J A Wargo.
Science, 2017 Nov 04; 359(6371). PMID: 29097493    Free PMC article.
Highly Cited.
Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma.
Yangyang Liu, Yue Hu, +5 authors, Li Liu.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207617    Free PMC article.
Towards personalized, tumour-specific, therapeutic vaccines for cancer.
Zhuting Hu, Patrick A Ott, Catherine J Wu.
Nat Rev Immunol, 2017 Dec 12; 18(3). PMID: 29226910    Free PMC article.
Highly Cited. Review.
Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens.
Giulia Escobar, Luigi Barbarossa, +12 authors, Luigi Naldini.
Nat Commun, 2018 Jul 26; 9(1). PMID: 30042420    Free PMC article.
Tumour flare reaction in cancer treatments: a comprehensive literature review.
Amina Taleb B.
Anticancer Drugs, 2019 Jul 28; 30(9). PMID: 31348010    Free PMC article.
The Genomic Landscape of Antigenic Targets for T Cell-Based Leukemia Immunotherapy.
Marie-Pierre Hardy, Krystel Vincent, Claude Perreault.
Front Immunol, 2020 Jan 11; 10. PMID: 31921187    Free PMC article.
Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses.
Anthony E Zamora, Jeremy Chase Crawford, +17 authors, Paul G Thomas.
Sci Transl Med, 2019 Jun 28; 11(498). PMID: 31243155    Free PMC article.
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Mariana L Oliveira, Padma Akkapeddi, +2 authors, João T Barata.
Adv Biol Regul, 2018 Sep 27; 71. PMID: 30249539    Free PMC article.
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.
Livius Penter, Catherine J Wu.
J Clin Invest, 2020 Jan 28; 130(4). PMID: 31985488    Free PMC article.
Regulatory T cells in pediatric AML are associated with disease load and their serial assessment suggests role in leukemogenesis.
Anuj Kumar Bansal, Surender Kumar Sharawat, +3 authors, Sameer Bakhshi.
Am J Blood Res, 2020 Sep 15; 10(4). PMID: 32923088    Free PMC article.
ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives.
Marco Folci, Giacomo Ramponi, +3 authors, Enrico Brunetta.
J Immunol Res, 2019 Jun 15; 2019. PMID: 31198793    Free PMC article.
Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect.
Pavan Bachireddy, Christina Ennis, +24 authors, Catherine J Wu.
Sci Transl Med, 2020 Sep 18; 12(561). PMID: 32938797    Free PMC article.
ADARs, RNA editing and more in hematological malignancies.
Phaik Ju Teoh, Mun Yee Koh, Wee Joo Chng.
Leukemia, 2020 Nov 04; 35(2). PMID: 33139858
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.
Alejandro Olivares-Hernández, Luis Figuero-Pérez, +5 authors, José Pablo Miramontes-González.
J Clin Med, 2021 May 01; 10(9). PMID: 33925214    Free PMC article.
Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis.
Marco Folci, Giacomo Ramponi, Virginia Solitano, Enrico Brunetta.
Clin Rev Allergy Immunol, 2021 Aug 31;. PMID: 34460071
60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.
Nicoletta Cieri, Katie Maurer, Catherine J Wu.
Cancer Res, 2021 Jun 11; 81(17). PMID: 34108142    Free PMC article.
Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy.
Peng Cheng, Peiliang Shen, +5 authors, Zhonghong Wei.
Front Cell Dev Biol, 2021 Sep 28; 9. PMID: 34568308    Free PMC article.
SLAMF6 in health and disease: Implications for therapeutic targeting.
Burcu Yigit, Ninghai Wang, Roland W Herzog, Cox Terhorst.
Clin Immunol, 2018 Oct 27; 204. PMID: 30366106    Free PMC article.